Genetic modifiers of sickle cell anemia in the baby hug cohort: Influence on laboratory and clinical phenotypes

Vivien A. Sheehan, Zhaoyu Luo, Jonathan M. Flanagan, Thad A. Howard, Bruce W. Thompson, Winfred C. Wang, Abdullah Kutlar, Russell E. Ware

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The recently completed BABY HUG trial investigated the safety and efficacy of hydroxyurea in infants with sickle cell anemia (SCA). To investigate the effects of known genetic modifiers, genomic DNA on 190 randomized subjects were analyzed for alpha thalassemia, beta-globin haplotype, polymorphisms affecting endogenous fetal hemoglobin (HbF) levels (XmnI, BCL11A, and HBS1L-MYB), UGT1A1 promoter polymorphisms, and the common G6PD A- mutation. At study entry, infants with alpha thalassemia trait had significantly lower mean corpuscular volume, total bilirubin, and absolute reticulocyte count. Beta-globin haplotypes associated with milder disease had significantly higher hemoglobin and %HbF. BCL11A and XmnI polymorphisms had significant effects on baseline HbF, while UGT1A1 promoter polymorphisms significantly influenced baseline serum bilirubin. At study exit, subjects randomized to placebo still exhibited laboratory effects of alpha thalassemia and other modifiers, while those assigned hydroxyurea had treatment effects that exceeded most genetic influences. The pain phenotype was influenced by HbF modifiers in both treatment groups. These data document that genetic polymorphisms do modify laboratory and clinical phenotypes even in very young patients with SCA. The hydroxyurea effects are more potent, however, indicating that treatment criteria should not be limited to certain genetic subsets, and supporting the use of hydroxyurea for all young patients with SCA.

Original languageEnglish (US)
Pages (from-to)571-576
Number of pages6
JournalAmerican Journal of Hematology
Volume88
Issue number7
DOIs
StatePublished - Jul 1 2013

Fingerprint

Hydroxyurea
Sickle Cell Anemia
alpha-Thalassemia
Phenotype
beta-Globins
Bilirubin
Haplotypes
Reticulocyte Count
Fetal Hemoglobin
Erythrocyte Indices
Genetic Polymorphisms
Hemoglobins
Therapeutics
Placebos
Safety
Pain
Mutation
DNA
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Sheehan, V. A., Luo, Z., Flanagan, J. M., Howard, T. A., Thompson, B. W., Wang, W. C., ... Ware, R. E. (2013). Genetic modifiers of sickle cell anemia in the baby hug cohort: Influence on laboratory and clinical phenotypes. American Journal of Hematology, 88(7), 571-576. https://doi.org/10.1002/ajh.23457

Genetic modifiers of sickle cell anemia in the baby hug cohort : Influence on laboratory and clinical phenotypes. / Sheehan, Vivien A.; Luo, Zhaoyu; Flanagan, Jonathan M.; Howard, Thad A.; Thompson, Bruce W.; Wang, Winfred C.; Kutlar, Abdullah; Ware, Russell E.

In: American Journal of Hematology, Vol. 88, No. 7, 01.07.2013, p. 571-576.

Research output: Contribution to journalArticle

Sheehan, Vivien A. ; Luo, Zhaoyu ; Flanagan, Jonathan M. ; Howard, Thad A. ; Thompson, Bruce W. ; Wang, Winfred C. ; Kutlar, Abdullah ; Ware, Russell E. / Genetic modifiers of sickle cell anemia in the baby hug cohort : Influence on laboratory and clinical phenotypes. In: American Journal of Hematology. 2013 ; Vol. 88, No. 7. pp. 571-576.
@article{3179f37895674278b85e404d2f344e9a,
title = "Genetic modifiers of sickle cell anemia in the baby hug cohort: Influence on laboratory and clinical phenotypes",
abstract = "The recently completed BABY HUG trial investigated the safety and efficacy of hydroxyurea in infants with sickle cell anemia (SCA). To investigate the effects of known genetic modifiers, genomic DNA on 190 randomized subjects were analyzed for alpha thalassemia, beta-globin haplotype, polymorphisms affecting endogenous fetal hemoglobin (HbF) levels (XmnI, BCL11A, and HBS1L-MYB), UGT1A1 promoter polymorphisms, and the common G6PD A- mutation. At study entry, infants with alpha thalassemia trait had significantly lower mean corpuscular volume, total bilirubin, and absolute reticulocyte count. Beta-globin haplotypes associated with milder disease had significantly higher hemoglobin and {\%}HbF. BCL11A and XmnI polymorphisms had significant effects on baseline HbF, while UGT1A1 promoter polymorphisms significantly influenced baseline serum bilirubin. At study exit, subjects randomized to placebo still exhibited laboratory effects of alpha thalassemia and other modifiers, while those assigned hydroxyurea had treatment effects that exceeded most genetic influences. The pain phenotype was influenced by HbF modifiers in both treatment groups. These data document that genetic polymorphisms do modify laboratory and clinical phenotypes even in very young patients with SCA. The hydroxyurea effects are more potent, however, indicating that treatment criteria should not be limited to certain genetic subsets, and supporting the use of hydroxyurea for all young patients with SCA.",
author = "Sheehan, {Vivien A.} and Zhaoyu Luo and Flanagan, {Jonathan M.} and Howard, {Thad A.} and Thompson, {Bruce W.} and Wang, {Winfred C.} and Abdullah Kutlar and Ware, {Russell E.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1002/ajh.23457",
language = "English (US)",
volume = "88",
pages = "571--576",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Genetic modifiers of sickle cell anemia in the baby hug cohort

T2 - Influence on laboratory and clinical phenotypes

AU - Sheehan, Vivien A.

AU - Luo, Zhaoyu

AU - Flanagan, Jonathan M.

AU - Howard, Thad A.

AU - Thompson, Bruce W.

AU - Wang, Winfred C.

AU - Kutlar, Abdullah

AU - Ware, Russell E.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The recently completed BABY HUG trial investigated the safety and efficacy of hydroxyurea in infants with sickle cell anemia (SCA). To investigate the effects of known genetic modifiers, genomic DNA on 190 randomized subjects were analyzed for alpha thalassemia, beta-globin haplotype, polymorphisms affecting endogenous fetal hemoglobin (HbF) levels (XmnI, BCL11A, and HBS1L-MYB), UGT1A1 promoter polymorphisms, and the common G6PD A- mutation. At study entry, infants with alpha thalassemia trait had significantly lower mean corpuscular volume, total bilirubin, and absolute reticulocyte count. Beta-globin haplotypes associated with milder disease had significantly higher hemoglobin and %HbF. BCL11A and XmnI polymorphisms had significant effects on baseline HbF, while UGT1A1 promoter polymorphisms significantly influenced baseline serum bilirubin. At study exit, subjects randomized to placebo still exhibited laboratory effects of alpha thalassemia and other modifiers, while those assigned hydroxyurea had treatment effects that exceeded most genetic influences. The pain phenotype was influenced by HbF modifiers in both treatment groups. These data document that genetic polymorphisms do modify laboratory and clinical phenotypes even in very young patients with SCA. The hydroxyurea effects are more potent, however, indicating that treatment criteria should not be limited to certain genetic subsets, and supporting the use of hydroxyurea for all young patients with SCA.

AB - The recently completed BABY HUG trial investigated the safety and efficacy of hydroxyurea in infants with sickle cell anemia (SCA). To investigate the effects of known genetic modifiers, genomic DNA on 190 randomized subjects were analyzed for alpha thalassemia, beta-globin haplotype, polymorphisms affecting endogenous fetal hemoglobin (HbF) levels (XmnI, BCL11A, and HBS1L-MYB), UGT1A1 promoter polymorphisms, and the common G6PD A- mutation. At study entry, infants with alpha thalassemia trait had significantly lower mean corpuscular volume, total bilirubin, and absolute reticulocyte count. Beta-globin haplotypes associated with milder disease had significantly higher hemoglobin and %HbF. BCL11A and XmnI polymorphisms had significant effects on baseline HbF, while UGT1A1 promoter polymorphisms significantly influenced baseline serum bilirubin. At study exit, subjects randomized to placebo still exhibited laboratory effects of alpha thalassemia and other modifiers, while those assigned hydroxyurea had treatment effects that exceeded most genetic influences. The pain phenotype was influenced by HbF modifiers in both treatment groups. These data document that genetic polymorphisms do modify laboratory and clinical phenotypes even in very young patients with SCA. The hydroxyurea effects are more potent, however, indicating that treatment criteria should not be limited to certain genetic subsets, and supporting the use of hydroxyurea for all young patients with SCA.

UR - http://www.scopus.com/inward/record.url?scp=84879327608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879327608&partnerID=8YFLogxK

U2 - 10.1002/ajh.23457

DO - 10.1002/ajh.23457

M3 - Article

C2 - 23606168

AN - SCOPUS:84879327608

VL - 88

SP - 571

EP - 576

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -